Table Of ContentFORMULARY
THE JOURNAL FOR MANAGED CARE AND HOSPITAL DECISION MAKERS
better than either drug alone for (abstr), 821 (Dec
granisetron financially attractive vs Ondansetron
abciximab annttii m7i2c r(oFbeibai)al ls carwoatrifda rina rterfvo r aTtxh eorfo sclerosis
ReoPro, update on, 131 (Mar) switching from IV to oral pravastatin sodiun
acarbose antithrombin I irvedil
Precose, update on, 639 (Nov) developing guidelines for use 20 (Sept Coreg at n. 745 (Dex
ACE inhibitors arrhythmia cefy [ til, flavored granules for
routine prescribing of, for CHF (abstr), 4 ) acute, amiodarone for Tx of, 509 (Sept) pension
acetaminophen dofetilide for Tx of, 23 Jan) Vantin Oral Suspension, update on, 495 (Sept
acute low back pain, for Tx of, 70 (Feb arthritis, rheumatoid ceftazidime
acvclovir cyclosporine or prednisolone as adjunctive thera bactam. v r Tx of hospital
low-dose, for prophylaxis against herpes simplex py for (abstr), 723 ower respiratory tract infections 563
virus. 720 (Nov) misoprostol prevents diclofenec-induced gastric
acute lymphocytic leukemia ulcers in (abstr), 830 (Dec)
asparaginase vs pegaspargase for Tx of, ir asparaginase
adults 388 (Jul) pe Zaspargasc vs ror Tx of acute lymphoc yt
adenosine injection leukemia in adults, 388 (Jul) in pediatric population, 615
Adenoscan, update on, 422 (Aug) atorvastatin hest pain
adverse drug reactions update on, 248 (May technetium ( 99m sestamibi for assessment of
computers, use of, for decreasing, 568 (Oct) atovaquone
reporting of, 226 (Apr); 454, 471 (Aug); 697 Mepron Suspension, update on, 427 (Aug chickenpox vaccine
(Nov) azelaic acid crean Varivax, update on, 305 (Jun
AG 1343 Azelex 20%, update on, 745 (Dec) Chlamydia trachomatis cervicitis
HIV infection, for Tx of, 722 (Nov azithromycin doxycycl ‘ ost-«
gency for Health Care Policy and Researct community-acquired pneumonia, as adjuvant May
quality care guidelines, publishes, 567 (Oct) therapy for, 817 (Dec) holesterol
alendronate sodium olestipol and lovastatin for lowering LDL (abstr)
Fosamax, update on, 746 (Dec) 236 (Apr
osteoporosis, for Tx of, 433 (Aug) BB as baseline for response t ipid-lowering
alteplase, recombinant therapy (abstr), 291 (May)
Activase, updateon , 304 (Jun) baclofen injection, USP lowering. cost-effectiveness of
alprostadil for injection Lioresal Intrathecal, update on, 304 (Jun
Caverject Sterile Powder, update on, 488 (Sept) benign prostatic hyperplasia simvastatin f{
amikacin sulfate terazosin vs finasteride for Tx of 54 (May
evaluatinugs e of, 114 (Feb) beta blockers statin the y for lowering
amiodarone silent ischemia, for Tx of (abstr 253 (Mav)
Cordarone IV, update on, 636 (Nov) underuse of, after MI, 370 (Jul) olestvramine tablets
focus on, 509 (Sept) bicalutamide
amlodipine Casodex, update on , 7 ) cidofovir IV
safety of, in patients with class-III or -IV 2g LHRH analogue, plus, fc f prostate cancer cytomegalovirus retinitis
failure, 253 (May) 377 (jul) Vistide, update on, 64
amlodipine besylate/benazepril HC]! biotech products iprofloxacin H¢
Lotrel, update on, 556 (Oct) developing guidelines for 520 (Sept) oro, update on
amoxicillin clavulanate potassium issues surrounding, 19 (Jan) three-day regimen of
acute otitis media, for Tx of, 721 (Nov) bisoprolol
amphetamine sulfate mixture HTN, alone or with hydrochlorothiazide { Tx isapride lid suspensi
Adderall/Obetrol update on, 68 (Feb) of (abstr), 5 Jan) Prop al 1, 755
amphotericin B lipid complex cisapride
conventional form, vs, for Tx of invasive candidi Propulsid
asis, 722 (Nov) clarithromycir
androgen deprivation therapy ymeprazole ilcers asso
prostate cancer, for Tx of, 567 (Oct) calcium channel blockers ciated wit lori *clic Aug)
antibiotics use of, in patients with HTN ( ) clobetaso
disease-based-outcome approach cancer
(Mar) breast
empiric use of, evaluated, 2 cyclophosphamide as adju ‘ deine phosphate 1
newer, physician prescribing of (Sept Br ntex ipdate on
pharmaceutical restriction program yntrol lung: nitive services
ling use of, 711 (Nov) chemother is clin ly and economically develo
restriction program for, 722 (Nov) (Dec) Jun)
therapeutic interchange program for, 92 (Feb ovarian issues surrounding
true costs of using, 310 (Jun paclitaxel for Tx of, 434 (Aug) lestipol/ lovastatin
anticoagulants prostate LDL cholesterol, for lowering (abstr), 236 (Apr
focus on, 657 (Nov) androgen deprivation therapy for Tx of, 5 ympliance, patient
anticoagulation (Oct) improving, 319 (Jun); 596 (Oct)
benefits outweigh costs of (abstr), 410 (Jul) bicalutamide/LHRH analogue for Tx of ymputerts
venous thromboembolism, for extended Tx of (Jul ADRs, f > in decreasing, 568 (Oct)
(abstr), 621 (Oct) hormone therapy is appropriate alternative for drug distribution system, for use in, 106 (Feb)
antidepressants low-grade, 760 (Dec) pain management, use of in, 70 (Feb)
pharmacologic rationale for Tx and product candidiasis, invasive software, adapting, for ADR reporting
selection of (Suppl), S-10 (Sept) amphotericin B lipid complex vs standard forn telephone program, and
antiemetic protection for Tx of, 722 (Nov) pliance, 496 (Sept)
combination of granisetron and dexamethasone carbachol congestive heart + f failure
832 Formutary © Voi. 30 © Decemper 1995
FORMULARY
THE JOURNAL FOR MANAGED CARE AND HOSPITAL DECISION MAKERS
better than either drug alone for (abstr), 821 (Dec
granisetron financially attractive vs Ondansetron
abciximab annttii m7i2c r(oFbeibai)al ls carwoatrifda rina rterfvo r aTtxh eorfo sclerosis
ReoPro, update on, 131 (Mar) switching from IV to oral pravastatin sodiun
acarbose antithrombin I irvedil
Precose, update on, 639 (Nov) developing guidelines for use 20 (Sept Coreg at n. 745 (Dex
ACE inhibitors arrhythmia cefy [ til, flavored granules for
routine prescribing of, for CHF (abstr), 4 ) acute, amiodarone for Tx of, 509 (Sept) pension
acetaminophen dofetilide for Tx of, 23 Jan) Vantin Oral Suspension, update on, 495 (Sept
acute low back pain, for Tx of, 70 (Feb arthritis, rheumatoid ceftazidime
acvclovir cyclosporine or prednisolone as adjunctive thera bactam. v r Tx of hospital
low-dose, for prophylaxis against herpes simplex py for (abstr), 723 ower respiratory tract infections 563
virus. 720 (Nov) misoprostol prevents diclofenec-induced gastric
acute lymphocytic leukemia ulcers in (abstr), 830 (Dec)
asparaginase vs pegaspargase for Tx of, ir asparaginase
adults 388 (Jul) pe Zaspargasc vs ror Tx of acute lymphoc yt
adenosine injection leukemia in adults, 388 (Jul) in pediatric population, 615
Adenoscan, update on, 422 (Aug) atorvastatin hest pain
adverse drug reactions update on, 248 (May technetium ( 99m sestamibi for assessment of
computers, use of, for decreasing, 568 (Oct) atovaquone
reporting of, 226 (Apr); 454, 471 (Aug); 697 Mepron Suspension, update on, 427 (Aug chickenpox vaccine
(Nov) azelaic acid crean Varivax, update on, 305 (Jun
AG 1343 Azelex 20%, update on, 745 (Dec) Chlamydia trachomatis cervicitis
HIV infection, for Tx of, 722 (Nov azithromycin doxycycl ‘ ost-«
gency for Health Care Policy and Researct community-acquired pneumonia, as adjuvant May
quality care guidelines, publishes, 567 (Oct) therapy for, 817 (Dec) holesterol
alendronate sodium olestipol and lovastatin for lowering LDL (abstr)
Fosamax, update on, 746 (Dec) 236 (Apr
osteoporosis, for Tx of, 433 (Aug) BB as baseline for response t ipid-lowering
alteplase, recombinant therapy (abstr), 291 (May)
Activase, updateon , 304 (Jun) baclofen injection, USP lowering. cost-effectiveness of
alprostadil for injection Lioresal Intrathecal, update on, 304 (Jun
Caverject Sterile Powder, update on, 488 (Sept) benign prostatic hyperplasia simvastatin f{
amikacin sulfate terazosin vs finasteride for Tx of 54 (May
evaluatinugs e of, 114 (Feb) beta blockers statin the y for lowering
amiodarone silent ischemia, for Tx of (abstr 253 (Mav)
Cordarone IV, update on, 636 (Nov) underuse of, after MI, 370 (Jul) olestvramine tablets
focus on, 509 (Sept) bicalutamide
amlodipine Casodex, update on , 7 ) cidofovir IV
safety of, in patients with class-III or -IV 2g LHRH analogue, plus, fc f prostate cancer cytomegalovirus retinitis
failure, 253 (May) 377 (jul) Vistide, update on, 64
amlodipine besylate/benazepril HC]! biotech products iprofloxacin H¢
Lotrel, update on, 556 (Oct) developing guidelines for 520 (Sept) oro, update on
amoxicillin clavulanate potassium issues surrounding, 19 (Jan) three-day regimen of
acute otitis media, for Tx of, 721 (Nov) bisoprolol
amphetamine sulfate mixture HTN, alone or with hydrochlorothiazide { Tx isapride lid suspensi
Adderall/Obetrol update on, 68 (Feb) of (abstr), 5 Jan) Prop al 1, 755
amphotericin B lipid complex cisapride
conventional form, vs, for Tx of invasive candidi Propulsid
asis, 722 (Nov) clarithromycir
androgen deprivation therapy ymeprazole ilcers asso
prostate cancer, for Tx of, 567 (Oct) calcium channel blockers ciated wit lori *clic Aug)
antibiotics use of, in patients with HTN ( ) clobetaso
disease-based-outcome approach cancer
(Mar) breast
empiric use of, evaluated, 2 cyclophosphamide as adju ‘ deine phosphate 1
newer, physician prescribing of (Sept Br ntex ipdate on
pharmaceutical restriction program yntrol lung: nitive services
ling use of, 711 (Nov) chemother is clin ly and economically develo
restriction program for, 722 (Nov) (Dec) Jun)
therapeutic interchange program for, 92 (Feb ovarian issues surrounding
true costs of using, 310 (Jun paclitaxel for Tx of, 434 (Aug) lestipol/ lovastatin
anticoagulants prostate LDL cholesterol, for lowering (abstr), 236 (Apr
focus on, 657 (Nov) androgen deprivation therapy for Tx of, 5 ympliance, patient
anticoagulation (Oct) improving, 319 (Jun); 596 (Oct)
benefits outweigh costs of (abstr), 410 (Jul) bicalutamide/LHRH analogue for Tx of ymputerts
venous thromboembolism, for extended Tx of (Jul ADRs, f > in decreasing, 568 (Oct)
(abstr), 621 (Oct) hormone therapy is appropriate alternative for drug distribution system, for use in, 106 (Feb)
antidepressants low-grade, 760 (Dec) pain management, use of in, 70 (Feb)
pharmacologic rationale for Tx and product candidiasis, invasive software, adapting, for ADR reporting
selection of (Suppl), S-10 (Sept) amphotericin B lipid complex vs standard forn telephone program, and
antiemetic protection for Tx of, 722 (Nov) pliance, 496 (Sept)
combination of granisetron and dexamethasone carbachol congestive heart + f failure
832 Formutary © Voi. 30 © Decemper 1995
ACE inhibitors, routine prescribing of, for Tx of doxycycline
(abstr +74 (Aug) st-effect
closing formulary reduce¢ of 2 (Dec) s (abstr
ontinued ¢ y (abstr), 621
(Oct)
Contract with America (GOP
health issues and, 118 (Feb
coronary heart
HMG-Co
(Fet
critical care pathways
development of, 504
S disease
methotrexate for Tx of (abstr
cromolyn sodium ophthalmic soh
Crolom, update on, 248 (May) j
cyclophosphamide BPH
breast cancer, as an r, 500 (Sept
cyclosporine
rheumato
723 (Nov)
cyclosporine capsules and oral s« drug distributic
emuision
Neoral Soft Gelatir
Solution, update
cysteamine Ditz
Cystagon, update «
cystic fibrosis
dornase alfa for Tx of
cytomegaiovirus retinitis
cidotovir for Tx of
evaluating criteria i
lrug use labeling
pediatric, FDA guide
dalteparin sodium injection luodenal ulcer
Fragmin, update on, 12 H pylori-associ
depression, major lansopraz le
issues in diagnosis of (Supp
nefazodone for Tx of
desmopressin acetate
DDAVP., update
dexrazoxone for injectior derly
Zinecard, update on, 495 (Sept) enalapril
diabetes mellitus, noninsulin-dependent 292 ' (May
glipizide to glyburide conversior »diipf ine
with, 405 (jul) (Mar)
metformin for Tx of, 383 l HTN, Tx
diazepam injectable misopr
Dizac, update on, 490 (Sept) with rrht eumaton
digoxin nimodipine facilitates
congestive heart failure continued therapy tor naiapri
(abstr). 621 (Oct
diltiazem HCl, controlled-release
Dilacor XR, update on, 248 (May
dinoprostone vaginal insert
Cervidil, update on, 304 (Jun)
dirithromycin tablets Ipp
Dynabac, update on, 639 (Nov evaluating service fe
focus on, 769 (Dec) pilepsy
disease-state management tiagabine H¢
developing program for, 17 (Jan); 326 (jun) -poprosteno
managed care organizations a 5 Aug) Flolan for
yharmaceutical industry's role in developing pro rgonovine
grams for (FormuFax), 409 Ergotrate upndaadatte
popularity of, in managed c: organizations osive esophagit
51 (May) lansoprazole for Tx of, 447 (Aug
and benefits of, 502 : (Sept) strogen (estradiol) transdermal
divalproex sodiun Climara, update
Depakote Tablets, update on strogen, progestir
dofetilide Prempro/Premphase
focus on, 23 Gan) strogen replacement therapy
dornase alfa benetits vs risks of, SO
wider use of, urged in patients with cystic fibro ardiac benefits of
sis, 15 Gan
dorzolamide ophthalmic solutior
Trusopt update on, 132 (Mar
doxazosin mesylate
Cardura, update on, 189 (Apr)
evaluating use of, 233 (Apr)
ember 1995 833
marketpl ice she acute
heart failure NSAIDs
amlodipine, safe irk
IV. 253 (May lisease
Helicobacter pylor ifections therapy
role and Tx patients with pepti
hepatitis
(abstr
interferon alpha interferor
hepatitis B, « ffective therapy
hepatitis B vaccine interferon beta (recombinant)
Engerix-B, update on multiple sclerosis, for Tx of, 655
hepatitis, non interferon beta-1b
interferon Betaser ipdate
sept) 1opromide
herpes simplex virus Ultravist Injection, update
famciclovir for Tx of genital, 587 (Oct) mde, nz
low-dose acycl for prophylaxis against
(Nov)
HIV-associated infections sient
dos3i4n9g (Jugnu idelines for iscIhV emti-cP A for tionsahdiaptp ting
HIV infection itraconazole
AG 1343 for Tx Sporanox, update
saquinavir, slower rate of resistance compared
with other proteinase inhibitors, 759 (Dec)
zidovudine, zalcitabine/saquinavir for Tx of
(Nov)
HMG-CoA reductase inhibitors JCAHO
coronary heart disease, for Tx
Indicat w Measurement Systen
HMOs 374 (Ju
profits of and enroliment in
Hodgkin s disease
peripheral blood progenitor cell transplantation
plus granulocyte colony-stimulatin actor {for
Tx of, 652 (Nov)
ketoprofen, extended release
hydromorphone HCl Oruvail Extended-Release Capsules, update
Dilaudid-HP, update on
194 (Apr
hypercholesterolemia ketorolac tr methamine
lovastatin vs niacin for Tx of, 21 (an) Torado ate on, 194
hypersecretory conditions replacement surgery
lansoprazole for Tx of Aug) enoxaparin f
hypertension
bisoprolol alone with hydrochlorothiazide
Tx of (a
calcium chann t f, in patients
with
elderly, Tx of, in, 148 (Mar) lamotrigine
Lamictal, update
enalapril or lisinopril for Tx of (abstr), 292 (May)
older drugs for Tx of, used less often, 414 (lun) lans¢ ypraze vie
focus on, 437 (Aug)
tively draus g,a dds-eoqnu entthiearla pyt her75a6p y (Dewco)r ks as effec *revacid Delayed-Release Capsules, update or
427 (Aug)
leuprolide acetate for { suspension
ipron Depot 3.75 m ipdate on, 368 Jul
-utenizing horm releasing hormone analogue
imipenem
seizure incidence associated wit! levothyroxine sodiur
immunomodulator therapy Levoxyl Lev ipdat
inflammatory bowel disease, fi lisinopri
784 (Dec) HTN, f 1 elderly 2 (May)
incentive programs loratadine 5 mg, exte nded-release pseudoephedrine
evaluating, 655 (Nov) sulfate 120 n
pharmacists Claritan, update 745 (Dec
infections Claritin-I 68 (Feb)
intra-abdor losartar } tassiun
meropenem for Tx of, 374 Cozaar ipdate
lower respiratory losartan px ium
piperacillin tazobactam vs ceftazi Hyzaat
of hospital-acquired, 563 (Oct iovastaur
piperacillin/ tazobactam vs colesup
lanate for Tx of, 719 (Nov)
respiratory irogenital
skin and soft-tissue
834 = Formutary @ Vot. 30 © Decemser 1995
SUBJECT INDEX TO VOLUME 30
(Feb) Parkinson's disease
t-PA, double bolus, for Tx of, 568 (Oct) medication compliance, and, 14 (Jan
underuse of beta blockers after, 370 (Jul) Ppegaspargasc
wartarin, cost-effectiveness of use after asparaginase, vs, for Tx of acute lympho ity of ire
(Jun) leukemia in adults, 388 (Jul) AHCPR publ
penicillin
bid better than gid, in Tx of streptoc
pharyngitis (abstr), 292 (May)
peptic ulcers
nalmefene HC] injection empiric therapy is cost effective (abstr ramipril capsule
Revex, update on, 368 (Jul) (Dec) Altace, updat«
naltrexone HCl H pylori infections and, 28 (Jan) ranitidine
ReVia, update on, 193 (Apr) pharmaceutical claims Zantac, update
naproxen, delayed-release using data from, for « management (D) immune glob
EC-Naprosyn, update on, 11 Jan) (sept) WinRho SD ipdate
nefazodone HCl pharmaceutical companies riluzok
focus on, 205 (Apr) incentive programs, and (FormuFax) 34 Jan Rilutek, update
Serzone, update on, 132 (Mar) mergers of, and effects on budgets, 200 (Apr nmexoione ophth
niacin product liability claims and, 238 (Apr) Vexol
lovastatin, vs, for Tx of hypercholestrolemia, 21 relationship with healthcare professionals, and
(Gan) 161 (Mar)
nimodipine pharmacist intervention progran
elderly, facilitates learning of, 134 (Mar) goals of, 433 (Aug)
Nitraic-frce interval pharmacist-prescribed drug class
definition of (letter), 51 (jan) pros and cons of, 653 (Nov)
nitroglycerin patches pharmacists
Minitran, update on, 69 (Feb) liability for substitutions, < FormuFax), 2%
nizatidine (May)
Axid, update on, 189 (Apr) reimbursement for services of, 315 (Jun) tease
norfloxacin pharmacoeconomics Sargramostim
Noroxin, update on, 492 (Sept) depressic m, the treatment of, issues in (Suppl Leukine/Imn
NSAIDs 20 (Sept) schizophrenia
acute low back pain, for Tx of, 70 (Feb) formulary decision making, and, 42 (Jan)
issues affecting, 20 (Jan)
studies of, standards for, 373 (Jul); 561 (Oct) FDA
Pharmacy & Therapeutics Committee (
adapting, in managed care, 138 (Mar)
omeprazole pharmacy benefit management companies seivziurgea batrin f«
clarithromycin, and, for Tx of Hp ylori-associated challenges and cost savings associated with, 12 seizures
duodenal ulcers, 431 (Aug) (jan) ncidence
cost effective for GERD, 760 (Dec) physicians (Mar
GERD, for Tx of, 216 (Apr) report cards for (FormuFax), 619 (Oct) selegiline
omeprazole delayed-release capsules pipeline Eldepryl, update
Prilosec, update on, 250 (May); 492 (Sept) agents in the, 10 (Jan); 68, 72 (Feb); 128 (Mar); 188 sertraline H(¢
ondansetron (Apr); 248 (May); 304 (Jun); 367 (Jul); 422 (Aug) Zoloft update
granisetron, vs, as financially attractive agent 488 (Sept) 556 (Oct): 636 (Nov 740 (Dex flurane volatil
(Feb) piperacillin/tazobactam Ultane, update
Zofran Tablets, update on, 305 (Jun) ceftazidime, vs, for Tx of hospital-acquired lower simvastatin
osteomyelitis respiratory tract infections, 563 (Oct) holesterc
new imaging agent for diagnosing, 722 (Nov) ticarcillin/clavulanate, vs, for Tx of lower respira 254 (May)
osteoporosis tory tract infections, 719 (Nov) Zocor, update
alendrenate sodium for Tx of, 433 (Aug) pneumonia dium chloride/s«
otitis media, acute community-acquired chloride
amoxicillin/clavulanate potassium for Tx of, 721 early switch to oral antibiotics in Tx of (abstr NuLytely
(Nov) 723 (Nov) somatropin
outcome measurements using azithromycin as adjuvant therapy Norditropin, updat
improving, 501 (Sept) of 817, (Dec) Statin therapy
outcomes research pneumocystc CAD. for
data from, wanted by pharmacists, 506 (Sept) chemoprophylactic regimens for, 28 (lan 253 (May
Who should conduct? (FormuFax), 171 (Mar) prophylaxis against (abstr), 544 (Sept) streptococcal pharyng
oxazolidinones practice guidelines nicillin bet
gram-positive organisms, a new class of drugs Minnesota MCO reports success creating 292 (May
effective against, 722 (Nov) (Dec) stroke
pravastatin sodium wartarin
carotid artery atherosclerosis, for Tx sumatriptar
(Feb) Imitrex
prednisolone
package inserts rheumatoid arthritis, as adjunctive therapy for
FDA proposes mandatory patient information in, (abstr), 723 (Nov)
622 (Oct) prenatal multivitamin/mineral supplement
paclitaxel Zenate, Advanced Formula, update on, 70 (Feb tacrine H(¢
ovarian cancer, for Tx of, 434 (Aug) prescribing practices Cognex, update
Taxol, update on, 132 (Mar) disease-based-outcome approach to, with antibi chnetium Tc99m
pain management otics, 149 (Mar) Neurolite, upd m, 193 (Ap
computers used in, 70 (Feb) documenting, 378 (Jul) chnetium azime injecti
tramadol for use in, 321 (Jun) how to change, 138 (Mar) Ceretec
pamidronate disodium for injection propok | chnetiun 99m sestamibi
Aredia, update on, 188 (Apr) Diprivan Injection, update « hest pain assessmento f
pancrelipase, microspheric delivery system psychiatric disorders razosin
Ultrase, update on, 755 (Dec) drugs for Tx of, in pipeline finasteride, vs, for t BPH
Formutary @ Vor. 30 © Decemper 1995 835
SUBJECT INDEX TO VOLUME 30
testosterone transdermal system new, compared with other therapies for Tx of vancomycin
Androderm, update on, 740 (Dec) acute MI, 258 (May) CDC recommends restricting use of, to slow
tetracycline HCl-impregnated peridontal fiber tramadol HCl spread of vancomycin-resistant organisms, 756
Actisite, update on, 488 (Sept) alternative dosing for (letter), 542 (Sept) (Dec)
thalidomide focus on, 321 (un) serum concentrations, need to monitor
Andrulis, update on, 557 (Oct) Ultram, update on, 250 (May) (Jan)
Synovir, update on, 557 (Oct) trimethoprim HCl varicella virus vaccine live
theophylline Primsol, update on, 640 (Nov) Varivax, update on, 428 (Aug)
Uni-Dur Extended-Release Tablets, update on trimetrexate glucuronate venlafaxine HCl
197 ( Apr) dosing guidelines for, 349 (Jun) Effexor, update on, 128 (Mar)
therapeutic interchange typhoid Vi polysaccharide vaccine vigabatrin
antibiotics, of, 92 (Feb) Tyvphim Vi, update on, 197 (Apr) focus on, 143 (Mar)
evaluation method for, 137 (Mar) vinorelbine tartrate
thiotepa Navelbine, update on, 130 (Mar)
Thioplex, update on, 369 (Jul)
thromboembolism, venous
extending anticoagulation for Tx of (abstr), 621 urethritis, nongonococcal
(Oct) single-dose azithromycin cures most men with
thrombolytics (abstr), 821 (Dec) warfarin sodium
pharmacologic therapy, vs, after myocardial urinary tract infections cardiovascular disease, for Tx of, focus on, 657
infarction, 80 (Feb) uncomplicated, three-day ciprofloxacin for Tx of (Nov)
risks vs benefits of, 257 (May) (abstr), 474 (Aug) cost-effective use of, post-MI, 310 (jun)
tiagabine HCl uterine leiomyoma Coumadin, update on, 422 (Aug); 556 (Oct)
intractable epilepsy, for Tx of, 133 (Mar) gonadotropin-releasing hormone, use of, before underused in stroke, 758 (Dec)
ticarcillin/clavulanate surgery for, 532 (Sept)
piperacillin/tazobactam, vs, for Tx of lower respi-
ratory tract infections, 719 (Nov)
tissue plasminogen activator (t-PA)
double bolus, for Tx of myocardial infarction, zidovudine/zalcitabine/saquinavir
568 (Oct) valacyclovir HCl] extended use of, for improved HIV suppression
ischemic stroke, for Tx of, 198 (Apr) Valtrex, update on, 640 (Nov) 720 (Nov)
UTHOR INDEX VOLUME 3
Al Berardi, Rosemary R.; Dunn-Kucharski, Valerie A Cefalu, W.: See Berelowitz, M
Omeprazole: Defining its role in gastroe Chase, Kathy: See Wooten, James M
sophageal reflux disease, 216 (Apr) Chernew, M.E.: See Fendrick, A.M
Agrawal, N.M.; van Kerckhove, H.E.J.; Erhardt, L.J Berelowitz, M.; Fischette, C.; Cefalu, W.; et al Cheung, Andrew: See O'Donovan, Carmel A
et al: Misoprostol coadministered with diclofenac Newer, controlled-release glipizide is superior to Chevallier M.: See Poynard T
for prevention of gastroduodenal ulcers: A one- older treatment (abstr), 236 (Apr) Chow, Moses S.S
year study (abstr), 830 (Dec) Bilianou, H.I.: See Kolovou, G.D See Baldinger, Sandra L
Ahkee, S.: See Ramirez, J.A Boston, David; Collins, Christine: Safety, efficacy See Barkin, Robert L
Albertson, Timothy E.: See Romac, Diane R and lipid profile of doxazosin at a VA medical See: Campbell, Margaret M
Anassi, Enock O.; Ericsson, Charles; Lal, Lincy center, 233 (Apr) Dopheide, Julie A
McCants, Ellecya: Using a pharmaceutical restric- Brandot, Milan E.: Shortened FDA approval King, Jeffrey H
tion program to control antibiotic use, 711 (Nov) process (FormuFax), 409 (Jul) Matthews, S. James
Andreski, Mike: Shortened FDA drug approval Breedveld, F.C.: Combination therapy for rheuma- Patel, Kalpana B
process (FormuFax), 290 (May) toid arthritis may be here to stay (abstr), 723 Tran, Hieu T
Arriola, Ed: The changing relationship between (Nov) > Sharma, Roopali
health care professionals and the pharmaceutical Breiman, R.F.; Butler, J.¢ Tenover, F.¢ et al See: Udeh, Elizabeth
industry, 161 (Mar) Pneumococcal strains show increasing resistance See: Wachsman, Matt
Attman, Robert L.: Report cards for physicians to drugs (abstr), 56 (Jan) hutka, Darryl S$ Selection of antihypertensive
(FormuFax), 620 (Oct) Brier, Kenneth Leo: Pharmaceutical management medications for the elderly, 148 (Mar)
strategies of industrialized countries, 606 (Oct) Cimato, Dominic A.: Do managed care formularies
Briglia, R.: Who should conduct outcomes ignore the individual patient? (FormuFax), 815
research? (FormuFax), 171 (Mar) (Dec)
Brown, Jean: Report cards for physicians Cohen, Lawrence J.: Pharmacoeconomic issues in
Bakst, Alan: Pharmacoeconomics and the formula (FormuFax), 620 (Oct) the treatment of depression (Suppl), S-20 (Sept)
ry decision-making process, 42 (Jan) Brown, Russell: Do managed care formularies Cohen, Michael R.: Mandatory medication error
Baldinger, Sandra L.; Chow, Moses S.S.; edited by ignore the individual patient? (FormuFax), 815 reporting (FormuFax), 53 (Jan)
Chow, Moses S.S.: Focus on anticoagulants (Dec) Cohen, Stuart H.: See King, Jeffrey H
Warfarin’s new indication for cardiovascular dis- Bryant, Bobby: See Lomaestro, Ben M Collins, Christine: See Boston, David
aese and enoxaparin’s new indication for knee Bryzinski, B.S.: See Frishman, W.H Colodner, R.: See Raz, R
replacement surgery, 657 (Nov) Butler, J.C.: See Breiman, R.F Coulson, L.R.: See Frishman, W.H
Barclay, Linh P.; Hatton, Randy C.; Doering, Paul Couto, A.J.: Manufacturers’ compensation programs
L.; Shands, Joseph W.: Physicians’ perceptions (FormuFax), 55 (Jan)
and knowledge of drug costs: Results of a sur- Crane, Vicki S.: See Gonzalez, Edgar R
vey, 268 (May)
Barkin, Robert L.: Alternative dosing for tramadol cairns, J.A.; Markham, B.A.: Benefits of long-term
aids effectiveness (letter), 542 (Sept) post-MI anticoagulation outweigh the costs
Barkin, Robert L.; edited by Chow, Moses S.S (abstr), 410 Gul)
Focus on tramadol: A centrally acting analgesic Calmes, Helen M.: Shortened FDA approval Dahigren, Thomas E.: Should FDA continue to reg-
for moderate to moderatly severe pain, 321 (Jun) process (FormuFax), 409 (Jul) ulate the exchange of scientific information?
Bedossa P.: See Poynard T Campbell, Margaret M.; edited by Chow, Moses (FormuFax), 619 (Oct)
Ben-Joseph, Rami; Segal, Richard; Russell, Wayne L S.S.: Focus on vigabatrin: A second-generation de Vries, R.J.M.; Dunselman, P.H.J van Veld-
Oh, Taeho: Evaluating the value, accuracy, and antiepileptic agent for treatment of refractory huisen, D.J.; et al: Felodipine reduces ischemia in
operational feasibility of DUE criteria, 280 (May) seizure disorders, 143 (Mar) older patients already on beta blockade (abstr)
836 — Formutary * VoL. 30 © Decemaer 1995
176 (Mar) record on drug approvals, 412 (Jul Kirwar R.: Combinatic ther
Diaz, Margarita Velazquez: Generic substitutions Health issues on hold, but lurking behind GOP's arthritis may be here to stay (abstr
(FormuFax), 291 (May) Contract with America, 118 (Fet Klaassen, Spencer: Should FDA wntir
DiMatteo, M. Robin: Patient adherence to pharma Industry successfully killing proposals t the ex inge f scient
cotherapy: The importance of effective communi counts on pharmaceuticals, 354 (lun FormuFax)
cation, 596 (Oct) Medicaid, FDA reform key issues building Klepser, Michael
Doering, Edmund III: Cooperation among MCOs in Congress, 294 (May) Kluger, Jeffre
(FormuFax), 620 (Oct) Medicaid, Medicare reform proposals stir Klutman, Ne
Doering, Paul L.: See Barclay, Linh P over prescription benefits, 546 (Sept
Dopheide, Julie A.; Stimmel, Glen L.; Yi, Donna D Pharmaceutical industry wins “round
edited by Chow Moses S.S Focus on nefa protections against product liability
zodone: A serotonergic drug for major depres (Apr)
sion, 205 (Apr) Who would approve new Kolovou
Douglas, M.B.: See Hawkins, D.W FDA? 58 (Jan) Baseline
Downing, Arlene: Manufacturers’ compensation Will politics sidetrack FDA reform? 47
programs (FormuFax), 54 (Jan) Geckler, R.W.: See Nichols, R.I
Dreiman, Randall: Role of pharmaceutical industry Gheorghiade, M.: See Ward, R.I Kramer Sharmz
in disease management programs (FormuFax) ;Obel, E.J.A.: See Portegies, M.C.M Kraynak aur See Reis, Andr
409 (Jul) soeckner, Byron J.: See Peters, Byron G
Dujovne, C.A.: See Schrott, H.G x0ldstein, Elliot: See Klutman, Neil E
Dunn-Kucharski, Valerie A.: See Berardi, Rosemary R sonzalez, Edgar R Crane, Vicki S Desigr
Dunselman, P.H.]J See de Vries, R.J.M disease management program: H
ed, 326 (Jun) IL al, Lincy: Sec Anass
LaPorta Mark A.: Rok
lisease manager
Elchanan, G See Raz, R
Ereshefsky, Larry: Antidepressants: A pharmacolog Hain, R.: Manufacturers ompensation
ic rationale for treatment and product selection (FormuFax), 55 (Jan)
(Supp), S-10 (Sept) Hall, W.D.: See Hawkins, D.W ormul
Erhardt L.J.: See Agrawal N.M Hatton, Randy C.: See Barclay, Linh P See Lomaestro, Ber
Ericsson, Charles: See Anassi, Enock O Havlichek, Daniel: See Stein, Gary I Moran, J.S
Erickson, Jan: Who should conduct outcomes Hawkins, D.W.; Hall, W.D.; Douglas, M.B irker, P.: See
research? (FormuFax), 171 (Mar) Two ACE inhibitors shown effective for omaestr Ben M.; Lesar
hypertension in elderly (abstr), 292 (May S.: Bryant, Bobby: Ceftr
Hennessey, Collin: See Stein, Gary I
Henry, R. Beth: See Wooten, James M
Hicks, C.B.: See Stamm, W.E
Fan-Havard, Patty: See O'Donovan, Carmel A Hillner, B.E.: See Smith, TJ
Feagan, B.G.: Rochon, ] Fedorak, R.N.; et al Hinrichs, Thomas | re formulari
Crohn's disease Methotrexate can reduce pred endangered species” list? (FormuFax
nisone requirements (abstr), 410 (Gul) Hirth, R.A.: See Fendrick, A.M Albert J.: Se
Fedorak, R.N.: See Feagan, B.G Hitt, Catherine M.: See Patel, Kalpana| ickian, Kathleer
Fendrick, A.M.; Chernew, M.E.; Hirth, R.A.; et al Howard, Lyn: See Malone, Margaret Margaret
Alternative management strategies for patients Hughes, ].M.: See McCraig, L.F Weral nutri 1 SeTVIC(
with suspected peptic ulcer disease (abstr), 822 Hunter, Dee A.: See Hunter, Walter Marangos, Markos Kalpana
(Dec) Hunter, Walter; Hunter, Dee A Markham, B.A
Fennerty, M. Brian; Melnyk, Clifford S.: Helic« Definintgh e nitrate-free ir \ letter Martin, D.H
bacter pylori: Review of triple, dual, 7-day, and Mandatory medication er reporting Maswoswe
other treatment strategies, 682 (Nov) Fax), 54 Gan)
Fiorello, Steven J.: Developing and implementing a
statewide formulary system: One state's exper
ence, 808 (Dec)
Fischette, C.: See Berelowitz, M
Fostinis. Y.P.: See Kolovou. G.D lacovelli, Le‘
Foulke, Garrett: See Romac, Diane R (FormuFax) ortened FDA
Frighetto, Luciana Nickoloff, Donna; Jewesson Iravani, A.; Tice, A.D rmul 290 (May
Peter: Antibiotic therapeutic interchange pro therapy with Avint Sec Gallant
gram: Six years of experience, 92 (Feb) incompt
Frishman, W.H.; Bryzinski, B.S.; Coulson, L.R.; et
al: Consider beta blocker plus diuretic as first
line therapy for hypertension (abstr), 56 (Jan)
Funk, Paula A.: See Orsini, Michael J
Jewesson, Peter: See Frighetto, Luciana
Johnson, Elizabeth > Saltiel, Emmanuel
Johnson, Jon D.: De managed care formularies
ignore the individual patient? (FormuFax 815
Gaddis, Gary M.: Let marketplace dictate reform (Dec) rd S$
not government (FormuFax), 172 (Mar) Jonker, J.J.C.: See van Bergen, P.F.M
Gallant, J.E McAvinue, $.M.; Moore, R.D.; et al
Pneumocystis carinii pneumonia prophylaxis
reduces mortality, costs (abstr), 544 (Sept)
Gallina, Joseph N.: See Orsini, Michael J
Garg, R.: Yusus, § Support is substantial for rou Kamp, 5 Are formularies or
tinely prescribing ACE inhibitors for CHF (abstr) species” list? (FormuFax), 816 (Dec
: (Aug) Kaufman, Rich: Shortened FDA drug
Gatty, Bob process (FormuFax), 290 (May)
Drive to refor the FDA gains momentum, 178 King, Jeffrey H Cohen, Stuart H.; edited by Neighbors, D.M
(Mar) Moses S.S.: Focus on ceftibuten: A third-g Ne wmar Mary
FDA says “! at the facts’ when judging its tion oral cephalosporin antibiotic, 85 (Feb) reporting (fF
Formu ary ® Vo.. 30 © Decemaer 1995 837
UTHOR INDEX TO VOLUME 30
Nichols, R.L.; Smith, J.W.; Geckler, R.W.: In with antithrombin III, 520 (Sept) Tugwell, P.; Pincus, T.; Yocum, D.; et al: Combina-
vestigational carbapenem antibiotic offers dosing Ross, Mary B.: See Szymusiak-Mutnick, Barbara A tion therapy for rheumatoid arthritis may be here
advantages (abstr), 724 (Nov) Rubin, Steven D.; Korelitz, Burton I.: Immuno- to stay (abstr), 723 (Nov)
Nickoloff, Donna: See Frighetto, Luciana modulator therapy in severe inflammatory bowel
Nicolau, David P.: See Patel, Kalpana B disease, 784 (Dec)
Nightingale, Charles H.: See Patel, Kalpana B Russell, Wayne L.: See Ben-Joseph, Rami
Nightingale, R.H.: Are formularies on “the endan
gered species” list? (FormuFax), 816 (Dec) Udeh, Elizabeth; Zaldonis, Anthony T edited by
Nuovo J.; Melnikow, J; Paliescheskey, M; et al Chow, Moses S.S.: Focus on lansoprazole: A new
Doxycycline shown most cost-effective for C tra proton pump inhibitor for gastric acid-related
chomatis cervicitis (abstr), 291 (May) Saltiel, Emmanuel: Potential cost savings using disorders, 437 (Aug)
GnRH agonists as preoperative therapy for uter-
ine leiomyomas, 532 (Sept)
Saltiel, Emmanuel; Johnson, Elizabeth; Shane, Rita
A team approach to adverse drug reaction surveil-
O'Connor, Mary C.: See Wooten, James M lance: Success at a tertiary care hospital, 226 (Apr) van Bergen, P.F.M.; Jonker, J.J.C.; van Hout, B.A.;
O'Donovan, Carmel A.; White, Monica L.; Cheung Schnabel, Joe: Manufacturers’ compensation pro- et al: Benefits of long-term post-MI anticoagula-
Andrew; Fan-Havard, Patty: Seizure incidence grams (FormuFax), 54 (Jan) tion outweigh the costs (abstr), 410 (jul)
with imipenem use at a VA hospital, 172 (Mar) Schraffenberger, Don W Generic substitutions van Hout, B.A.: See van Bergen, P.F.M
Oh, Taeho: See Ben-Joseph, Rami (FormuFax), 291 (May) van Kerckhove H.E.J.: See Agrawal N.M
Okpara, Alphonsus U.; Maswoswe, Jordan J.; Schrott, H.G.; Stein, E.A.: Dujovne, C.A.; et al van Veldhuisen, D.J.: See de Vries, R.J.M
Stewart, Kenneth: Criteria-based antimicrobial IV Combination therapy with low-dose colestipol Velasquez, William S.: See Peters, Byron G
to oral conversion program, 343 (Jun) and lovastatin lowers LDL (abstr), 236 (Apr) Vissing, Rick: See Matuschka, Paul
Orsini, Michael J.; Funk, Paula A.; Thorn, Deborah Schulman, S.; Rhedin, A.-S.; Lindmarker, P.; et al Vrabel, Rayburn B.; Mackowiak, Leslie: Automation
B.; Gallina, Joseph N.: An ADR surveillance pro- Extending anticoagulant regimen helps prevent in pharmacy: Two institutions’ experiences with
gram: Increasing quality, number of incidence thromboembolisms (abstr), 621 (Oct) novel distribution systems, 106 (Feb)
reports, 454 (Aug) Segal, Richard: See Ben-Joseph, Rami
Owings, John T.: See Romac, Diane R Shands, Joseph W.: See Barclay, Linh P
Shane, Rita: See Saltiel, Emmanuel
Sharma, Roopali; Kramer, Marty; edited by Chow
Moses S.S.: Focus on dirithromycin: A new once- Wachsman, Matt; edited by Chow, Moses S.S
daily macrolide antibiotic, 769 (Dec) Focus on famciclovier: Review of its use in geni-
Paliescheskey M: See Melnikow, Nuovo J Sijbring, P: See Portegies, M.C.M tal herpes simplex virus therapy, 587 (Oct)
Patel, Kalpana B.; Nicolau, David P.; Klepser, Smith, J.W.: See Nichols, R.I Wade, William E.; McCall, Charles Y.: How a CQI
Michael E.; Marangos, Markos N; Hitt, Catherine Smith, TJ.; Hillner, B.E.; Neighbors, D.M.; et al program improved aminoglycoside use in a com-
M.; Nightingale, Charles H.; edited by Chow Economic evaluation of a randomized clinical munity hospital, 114 (Feb)
Moses S.S.: Focus on fleroxacin: A new once- trial comparing vinorelbine, vinorelbine plus cis- Ward, R.E.; Gheorghiade, M.; Young J.B.; et al
daily fluoroquinolone antibiotic, 261 (May) platin, and vindesine plus cisplatin for non-small- Continuing digoxin therapy in patients wtih sta-
Pearson, Noel: Should FDA continue to regulate cell lung cancer (abstr), 822 (Dec) ble CHF is cost-effective (abstr), 621 (Oct)
the exchange of scientific information? Snow, Karla S.: See Lomaestro, Ben M Wedworth, Emily Burton: Legislation on equal
(FormuFax), 619 (Oct) Srinath, L.: See Ramirez, J.A access to discounts (FormuFax), 55 (Jan)
Peroutka, Julie A.; Mutnick, Alan H.: Use of deci Stamm, W.E.; Hicks, C.B.; Martin, D.H.; et al: Azith- Wechsler, Jill
sion analysis to evaluate the costs and benefits of romycin for empirical treatment of the nongonoc- FDA considers effects of managed care market-
filgrastim (G-CSF) therapy, 394 (Jul) cal urethritis syndrome in men (abstr), 821 (Dec) place on drug promotional practices, 840 (Dec)
Peters, Byron G.; Goeckner, Byron J.; Ponzillo Stein, E.A.: See Schrott, H.G FDA puts forth proposal to mandate patient
John J.; Velasquez, William S.; Wilson, Andrew Stein, Gary E; Havlichek, D; Hennessey, Collin information, 622 (Oct)
L.: Pegaspargase versus asparaginase in adult Using azithromycin as adjuvant, empiric therapy Increased contributions, decreased fees, managed
ALL: A pharmacoeconotmnic assessment, 388 (Jul) to treat community-acquired pneumonia, 817 care are key Medicare reform issues, 730 (Nov)
Pincus, T.: See Tugwell, P (Dec) Wells, Barbara G.: Issues in diagnosis of major
Ponzillo, John J.: See Peters, Byron G Stewart, Ken: See Anassi, Enock O depression (Suppl), S-3 (Sept)
Poole, Patricia: See Romac, Diane R Stewart, Kenneth: See Okpara, Alphonsus l White, Monica L.: See O'Donovan, Carmel A
Portegies, M.C.M.; Sijbring, P; Gobel, E.J.A.; et al Stimmel, Glen L.: See Dopheide, Julie A Wilson, Andrew L.: See Peters, Byron G
Use beta blockers for silent ischemia in patients Stoogenke, Marvin M.: Who should conduct out- Wilson, Ellis, Jr.: Do managed care formularies
with stable angina (abstr), 176 (Mar) comes research? (FormuFax), 172 (Mar) ignore the individual patient? (FormuFax), 815
Potts, Truman A.: Legislation on equal access to Szymusiak-Mutnick, Barbara A.; Ross, Mary B (Dec)
discounts (FormuFax), 55 (Jan) Increased adverse drug reaction reporting through Witkowski, Paul: Should FDA continue to regulate
Poynard T.; Bedossa P.; Chevallier M.; et al: Use wall-mounted ADR reporting cards, 471 (Aug) the exchange of scientific information? (Formu-
high-dose, long-term interferon for chronic non Fax), 619 (Oct)
A, non-B hepatitis (abstr), 544 (Sept) Wong, J.B.; Koff, R.S.; Tiné, F.; et al: Interferon
shows clinical and economic advantages in
hepatitis B therapy (abstr), 724 (Nov)
Taniguichi, George: Do managed care formularies Wong, T.: Are formularies on “the endangered
ignore the individual patient? (FormuFax), 815 species” list? (FormuFax), 816 (Dec)
Ramirez, J.A.; Srinath, L.; Ahkee, S.; et al: Com- (Dec) Wooten, James M.; Chase, Kathy; O'Connor, Mary
munity-acquired pneumonia: Early switch to oral Tenover, F.C.: See Breiman, R.F C.; Henry, R. Beth: Dosing guidelines for foscar-
antibiotics can cut costs (abstr), 723 (Nov) Tetenman, Stanley L.: Discriminatory pricing poli- net and trimetrexate, 349 (Jun)
Raz, R.; Elchanan, G.; Colodner, R.; et al: Twice cies are discriminatory (letter), 543 (Sept)
daily penicillin superior to QID regimen for Tharratt, Steven: See Romac, Diane R
streptococcal phraryngitis (abstr), 292 (May) Thorn, Deborah B.: See Orsini, Michael J
Reis, Andrea J.; Kraynak, Maura A.: Adapting a Tice, A.D.: See Iravani, A
commercially available software program to Tiné, F.: See Wong, J.B
improve ADR reporting, 697 (Nov) Tran, Hieu T.; Kluger, Jeffrey; Chow, Moses S.S Yi, Donna D.: See Dopheide, Julie A
Rhedin, A.-S.: See Schulman, S$ edited by Chow, Moses S.S YYoocuunmg, J.BD..:: SSeeee TWuagrwde,l l,R .E P
Rochon, J.: See Feagan, B.G Focus on dofetilide: A selective class III antiar-
Roe, Whitney: Manufacturers’ compensation pro rhythmic agent, 23 (Jan) Yusus, S.; See Garg, R
grams (FormuFax), 55 (Jan) Focus on IV amiodarone: A new formulation for
Romac, Diane R.; Poole, Patricia; Owings, John T acute arrhythmia treatment, 509 (Sept)
Mahackian, Kathleen; Foulke, Garrett; Tharratt Tse, Ted; Madura, Albert J.: Initiating a drug blood
Steven; Alberts: Timothy E.: Developing guide- level monitoring program through CQI, 284
lines for biotechnology drug use: Experience (May) Zaldonis, Anthony T.: See: Udeh, Elizabeth
838 — Formutary © VoL. 30 © Decemser 1995
